Discovery Strategies to Maximize the Clinical Potential of T-Cell Engaging Antibodies for the Treatment of Solid Tumors.

Voynov, Vladimir; Adam, Paul J; Nixon, Andrew E; Scheer, Justin M

Voynov, Vladimir; Adam, Paul J; Nixon, Andrew E; Scheer, Justin M.

Afiliación

Voynov V; Biotherapeutics Discovery, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, CT 06877, USA.
Adam PJ; Cancer Immunology & Immune Modulation, Boehringer Ingelheim RCV GmbH & Co KG, Dr. Boehringer-Gasse 5-11, 1121 Vienna, Austria.
Nixon AE; Biotherapeutics Discovery, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, CT 06877, USA.
Scheer JM; Biotherapeutics Discovery, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, CT 06877, USA.

Antibodies (Basel) ; 9(4)2020 Nov 18.

Article en En | MEDLINE | ID: mdl-33217946

Palabras clave

T-cell engagers; antibody engineering; bispecific antibodies; immunological synapse; immunotherapy; oncology

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Antibodies (Basel) Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google